Susan Mahony, a board member at Axsome Therapeutics Inc. (NASDAQ: AXSM), recently completed the liquidation of restricted stock unit (RSU) settlements through a series of share sales in early June 2026. The transactions, executed via a pre-approved 10b5-1 trading plan, totaled $145,017 and were primarily structured to cover tax liabilities associated with the vesting of grants originally issued on June 6, 2025.
The sales occurred across two consecutive days. On June 9, Mahony sold 300 shares at $237.21 per share. The following day, June 10, she liquidated an additional 300 shares at $246.18 per share. These dispositions followed the settlement of 1,429 RSUs on June 8, which converted into common stock on a one-for-one basis upon their one-year anniversary vesting date. Post-transaction, Mahony retains direct ownership of 829 Axshare shares.
The stock currently trades at $246.34, hovering near its 52-week high of $256 and reflecting a 128% return over the trailing twelve months. According to InvestingPro analysis, the equity appears fairly valued at current levels, with 14 additional ProTips available to subscribers.
These executive liquidity events coincide with broader corporate developments at Axsome Therapeutics. The company reported mixed Q1 2026 financial results, posting a net loss of $1.26 per share against a forecasted loss of $0.83 per share. Revenue came in at $191.2 million, slightly below the expected $193.46 million.
In a significant legal resolution, Axsome settled all patent litigation related to SUNOSI, its solriamfetol product. The disputes had centered on Abbreviated New Drug Applications filed by competitors seeking to market generic versions. Following the settlement, H.C. Wainwright reiterated a Buy rating on the stock, maintaining a $290 price target.
Operational initiatives include support for migraine awareness in June, featuring the Headache in the City educational campaign. Axsome's headquarters at One World Trade Center will be illuminated in purple to mark the observance. Additionally, Morgan Stanley reported year-over-year growth in US antipsychotic prescriptions, a trend that may influence Axsome's competitive positioning in the broader neurological market.